Skip to main navigation
Skip to search
Skip to main content
Technical University of Munich Home
Help & FAQ
Link opens in a new tab
English
Deutsch
Search content at Technical University of Munich
Home
Profiles
Research units
Projects
Research output
Equipment
Prizes
Activities
Press/Media
In vitro and animal studies with antiprogestins
H. Michna
, Y. Nishino
, K. Parczyk
, M. R. Schneider
Deutsche Sporthochschule Köln
Therapeutic Research Group Women's Healthcare Bayer Schering Pharma AG
Research output
:
Contribution to journal
›
Article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'In vitro and animal studies with antiprogestins'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Antiestrogen
33%
Antiglucocorticoid
33%
Antiprogestins
100%
Apoptosis Induction
33%
Combined Treatment
66%
Endocrine Therapy
33%
ER+ Breast Cancer
33%
Growth Inhibition
33%
Inhibitory Efficacy
33%
Long-term Treatment
33%
Mammary Carcinoma
66%
Medroxyprogesterone Acetate
33%
Mifepristone
33%
Onapristone
66%
Oophorectomy
33%
Pregnancy Disorders
33%
Progesterone Antagonist
100%
Second-line Treatment
33%
Specific Compounds
33%
Treatment Regimen
66%
Tumor
33%
Tumor Growth
33%
Tumor Growth Inhibition
33%
Tumor Inhibition
33%
Medicine and Dentistry
Antiestrogen
25%
Antigestagen
100%
Breast Cancer
25%
Breast Carcinoma
50%
Cancer Inhibition
25%
Depo-Provera
25%
Hormone Therapy
25%
In Vitro
100%
Medroxyprogesterone Acetate
25%
Mifepristone
50%
Onapristone
50%
Ovariectomy
25%
Programmed Cell Death
25%
Tamoxifen
25%
Tumor
25%
Tumor Progression
50%
Veterinary Science and Veterinary Medicine
Antiestrogen
25%
Antiglucocorticoid
25%
Breast Cancer
25%
Breast Carcinoma
50%
In Vitro
100%
Medroxyprogesterone Acetate
25%
Mifepristone
50%
Mouse
25%
Oophorectomy
25%
Progesterone
75%
Tamoxifen
25%
Tumor
100%
Pharmacology, Toxicology and Pharmaceutical Science
Antiestrogen
25%
Antigestagen
100%
Antiglucocorticoid
25%
Breast Cancer
25%
Breast Carcinoma
50%
Cancer Inhibition
25%
Lead Compound
25%
Medroxyprogesterone Acetate
25%
Mifepristone
50%
Onapristone
50%
Tamoxifen
25%
Tumor Growth
50%